Localization of b-catenin in the cell is a key determinant in its decision to function as a critical mediator of cell adhesion at the surface or a transcription activator in the nucleus. SYT-SSX2 is the fusion product of the chromosomal translocation, t(X;18)(p11.2;q11.2), which occurs in synovial sarcoma, a soft tissue tumor. SYT-SSX2 is known to associate with chromatin remodeling complexes and is proposed to be involved in controlling gene expression. We report that SYT-SSX2 plays a direct role in b-catenin regulation. When expressed in mammalian cells, SYT-SSX2-induced b-catenin recruitment to the nucleus. Interestingly, known target genes of canonical Wnt were not activated as a result of SYT-SSX2 expression, nor was the nuclear localization of b-catenin due to one of the signaling pathways normally implicated in this event. b-Catenin accumulation in the nucleus led to the formation of a transcriptionally active nuclear complex that contained SYT-SSX2 and b-catenin. More importantly, depletion of SYT-SSX2 in primary synovial sarcoma cells resulted in loss of nuclear b-catenin signal and a significant decrease in its signaling activity. These results unravel a novel pathway in the control of b-catenin cellular transport and strongly suggest that SYT-SSX2 contributes to tumor development, in part through b-catenin signaling.
Introduction
Nuclear translocation and retention is at the center of b-catenin function. Its ability to integrate the multiple Wnt pathways that involve progenitor stem cell proliferation, differentiation and axis specification relies on its presence in the nucleus where it associates with TCF/ LEF1 and induces gene expression. Moreover, b-catenin shuttling between the nucleus and the cytoplasm is key for maintaining the balance between its role in cell-tocell adhesion at the surface and its oncogenic nuclear activation that could lead to tumor formation in somatic cells (van Es et al., 2003) .
SYT-SSX is the product of a t(X;18)(p11;q11) translocation that occurs in synovial sarcoma, an aggressive soft tissue tumor. It is the result of a fusion between the SYT (SYnovial sarcoma Translocated) gene on chromosome 18 and an SSX gene on chromosome X. The chromosomal rearrangement is detected in almost all cases of synovial sarcoma. Thus SYT-SSX is considered to play a central role in the development of this cancer. However, the mechanism of tumor initiation by SYT-SSX is still unknown. SYT and SYT-SSX are nuclear proteins that associate with chromatin remodeling complexes (SWI/SNF) and are thought to be involved in the control of gene expression (dos Santos et al., 2001; Ladanyi, 2001) .
The SSX gene family is composed of nine contiguous members (SSX1-9). Although the chromosomal arrangement of the SSX genes could in principle allow for heterogeneity at the breakpoint, the translocation in synovial sarcoma has so far been detected either in the SSX1 or SSX2, and, rarely in the SSX4 gene . The identity of the rearranged SSX gene has significant clinical impact. Although SYT-SSX2 is linked to a monophasic histologic subtype, SYT-SSX1 is often detected in biphasic tumors and is correlated with a shorter metastasis-free period and patient survival . SYT-SSX1 was recently shown to possess proliferative and transforming activity (Nagai et al., 2001) , as well as to increase the stability of cyclin D1 (Xie et al., 2002) .
In the majority of synovial sarcomas, a striking cytoplasmic and nuclear accumulation of b-catenin is observed. Remarkably, b-catenin accumulation occurs in the absence of genetic mutations in the tumor suppressor APC or the b-catenin gene. This led to the belief that nuclear accumulation of b-catenin in synovial sarcomas is the consequence of a distinct pathway proper to the tumor (Hasegawa et al., 2001) .
In this report, we provide evidence that the fusion protein SYT-SSX2, through a dominant gain of function, recruits b-catenin to the nucleus. There, both proteins coreside in distinct foci and b-catenin signaling is activated. This regulation of b-catenin function is apparently independent of canonical Wnt activation and reveals one mechanism by which SYT-SSX likely initiates tumorigenesis.
Results
Expression of the synovial sarcoma fusion protein SYT-SSX2 causes b-catenin nuclear accumulation Synovial sarcoma is thought to originate from mesenchymal stem cells. Therefore, we decided to conduct our studies using NIH3T3 as target cells, in search for SYT-SSX function. To this end, NIH3T3 cells were transiently infected with POZ-retroviral vectors (Ikura et al., 2000) expressing full-length (FL-) SYT, SYT-SSX2, or SYTdl8 (corresponding to the full-length SYT lacking the last carboxy-terminal eight amino acids, which are missing in the SYT-SSX fusion product). Remarkably, 48 h postinfection, an intense endogenous nuclear b-catenin signal appeared in 20-30% of cells expressing SYT-SSX2. There was no obvious cytoplasmic accumulation of b-catenin in these cells, and no noticeable increase in its total cellular level ( Figure 1a , panel SYT-SSX2). By contrast, nuclear b-catenin was undetected in cells infected with the retroviral vector alone, SYT or SYTdl8 (Figure 1a , panels V, SYT and SYTdl8, respectively). All three exogenous proteins were expressed at equivalent levels ( Figure 1b ) and the infection efficiency was 80-90% with all four vectors.
These results indicate that SYT-SSX2 expression induces nuclear accumulation of endogenous b-catenin. The change in localization of cellular b-catenin exerted by SYT-SSX2 occurs through a gain of function caused by SSX addition rather than deletion of the SYT COOH-terminal eight amino acids.
SYT-SSX2 recruits b-catenin to its nuclear foci where both proteins form an in vivo complex SYT and SYT-SSX are known to reside in nuclear foci as a result of their association with chromatin modifying complexes. Their nuclear structures, however, are not In every experiment a total of 1000 cells were counted for each construct. The nuclear localization of SYT, SYT-SSX2 and SYTdl8 is due to the presence of the N-terminal nuclear localizing region (amino acids 51-90; dos Santos et al., 2000) present in all three polypeptides. A faint cytoplasmic HA signal, however, was noticed in the NIH3T3 cells infected with POZ-SYT and POZ-SYTdl8. This is likely due to minimal leakage of human proteins expressed in murine cells. Such leakage was not detected in SYT-SSX2 infected cells where the HA staining was exclusively nuclear. This could be explained by the additional presence of the nuclear localizing SSXRD region (the 34 C-terminal amino acids) of SSX2. SSXRD likely provides a more efficient binding of SYT-SSX2 on chromatin and better nuclear retention (Soulez et al., 1999) . Note the absence of cytoplasmic HA staining when SYT was expressed in U2OS, a human osteosarcoma cell line (Figure 2 , compare panels a and b). SYTdl8 expression gave results similar to SYT (data not shown). Images were taken at Â 20 magnification with the Zeiss Axioplan 2 fluorescent microscope and merging of DAPI and b-catenin signals was performed using the same contrast. (b) Levels of expressed POZ, POZ-SYT, POZ-SYT-SSX2, and POZ-SYTdl8 in infected NIH3T3 cells, visualized by the FLAG M2 Ab. Note that a FLAG/HA-positive cytoplasmic low molecular weight vector-derived polypeptide is generated from the POZ plasmid. Its synthesis was interrupted when the SYT-derived cDNAs were inserted in the POZ backbone plasmid.
SYT-SSX2 regulates b-catenin location and function D Pretto et al identical and they exhibit cell-to-cell variability in size and number (dos Santos et al., 1997; Thaete et al., 1999) . In our studies, SYT and SYT-SSX2 were both seen in small foci evenly distributed in the nuclear compartment ( Figure Together, these data reveal that SYT-SSX2 resides in unique structures within the nucleus. These structures likely represent SYT-SSX2 protein complexes of different biological activities. SYT-SSX2 recruits b-catenin to its own distinct foci in the nucleus. The association of b-catenin in a subpopulation of these foci signifies that it participates in mediating, in part, SYT-SSX function.
In vivo complex formation between SYT-SSX2 and b-catenin could be confirmed at the biochemical level. A specific antibody (SV11) that recognizes SYT, SYT-SSX2 and SYTdl8, was able to co-precipitate b-catenin and SYT-SSX2, but failed to do so significantly in NIH3T3 cells expressing SYT, SYT-dl8 or POZ vector ( Figure 2c ). Similarly, a specific SYT-SSX2/b-catenin complex was detected when both polypeptides were coexpressed along with TCF4 ( Figure 2d ). Further in vitro studies, however, showed that SYT-SSX does not bind directly to b-catenin, implying that in vivo, other partners likely serve as a bridge between the two proteins to form a nuclear complex (Figure 2e ).
b-catenin nuclear recruitment by SYT-SSX2 is independent of canonical Wnt In human cancers, accumulation of b-catenin in the nucleus is normally due to incapacitation of its degradation machinery. This occurs when GSK-3b-dependent components of the Wnt pathway, such as APC, axin or b-catenin itself are mutated. As a result, b-catenin is stabilized, reaches the nucleus where it associates with TCF/LEF1 and induces the expression of proliferation genes such as cyclin D1 and MYC, or the matrilysin (MMP7) gene. These events are implicated in the formation of colon, pancreatic and liver cancers (Doucas et al., 2005) .
In SYT-SSX2-expressing cells, the cellular levels and the stability of b-catenin remained the same. Furthermore, there was no noticeable increase in any of the known Wnt targets; cyclin D1, MYC (Figure 3a ), or matrilysin (data not shown). The level of unpho- (Figure 3a) , considered the active form of the protein in the nucleus (Staal et al., 2002) was also unchanged. Moreover, in vitro assays showed normal GSK-3b kinase activity and constant levels of its target b-catenin species phosphorylated on residues S33, S37, T41 and S45 (data not shown).
In summary, SYT-SSX2 recruitment of nuclear bcatenin did not appear to be a consequence of canonical Wnt pathway activation.
In sarcomas, aberrant activation of growth factor and receptor tyrosine kinase (RTK) signaling pathways and their downstream effectors is frequently observed (Allander et al., 2002) . It is also known that tyrosine phosphorylation regulates the behavior of b-catenin. A number of RTKs such as those of epidermal growth factor (EGF; Hoschuetzky et al., 1994) , insulin-like growth factor (IGF; Playford et al., 2000) , and hepatocyte growth factor-like ligands (RON and MET; Danilkovitch-Miagkova et al., 2001) were shown to phosphorylate b-catenin and may lead to its nuclear translocation. Tyrosine residue 142 (Tyr 142; Piedra et al., 2003) phosphorylation is a common target. Recently, the oncogene homolog BCL9-2 was also reported to phosphorylate b-catenin on Tyr 142, and to assist in its transport to and retention in the nucleus (Brembeck et al., 2004) .
In our studies, however, we were unable to detect a change in the tyrosine phosphorylation status of cellular b-catenin (Figure 3a) , excluding the possibility that one of the aforementioned pathways is altering b-catenin location in SYT-SSX expressing cells. In addition, levels of TCF4 remained constant ( Figure 3a) and there was no detectable LEF (data not shown). The latter is known to escort b-catenin and retain it in the nucleus as a result of integrin-linked kinase (ILK)-mediated induction (D'Amico et al., 2000) .
To complete our studies, we treated SYT-SSX2-expressing cells with specific pathway inhibitors and monitored their effect on b-catenin nuclear accumulation. Addition of LY29004 or wortmannin (PI3Kinase/ AKT inhibitors), SB203580 (the p38 MAPK (mitogenactivated protein kinase) inhibitor), and UO126 or PD98059 (inhibitors of ERK (extracellular signal regulated kinase)), failed to abolish nuclear b-catenin (Figure 3b and data not shown).
Together, these data indicate that the nuclear translocation protein SYT-SSX2 controls b-catenin localization through a novel mechanism independent of canonical Wnt or other pathways known to regulate this process.
SYT-SSX2 activates b-catenin signaling in a p300-dependent manner Nuclear translocation of b-catenin is normally required but not sufficient for its transcriptional activation function (Prieve and Waterman, 1999) . In order to determine whether SYT-SSX nuclear recruitment of b-catenin activates its signaling, we conducted transcription studies where we compared the effect of SYT, SYT-SSX2 and SYTdl8 on b-catenin/TCF4 activity, using the TOP-FLASH reporter construct. Although SYT and SYTdl8 exhibited a modest stimulation over background effect, we observed a steep surge in b-catenin activation by SYT-SSX2 (Figure 4a ). All three proteins were expressed at adequate levels (Figure 4a, inset) .
SYT and SYT-SSX2 are not DNA-binding transcription factors. It is therefore thought that they exert their gene regulation function by associating with coactivator protein partners (Clark et al., 1994) . We have previously identified SYT as one of the transcriptional coactivator p300-interacting proteins. SYT binds p300 at its NH2-terminus, a region also present in SYT-SSX2 (Eid et al., 2000) . Recently, we found that, similar to SYT, SYT-SSX2 makes direct contact with p300 in its C/H1 and C/H3 (unpublished data; Barco and Eid) domains. In order to acquire insight into the regulation of the nuclear b-catenin/SYT-SSX2 complex, we therefore asked whether p300 contributed to its activation. For this, we inhibited p300 by coexpressing in the TOP-FLASH activation assay described above, wt 12S-E1A, the transforming adenovirus polypeptide known to bind p300 and inhibit its function. This resulted in complete suppression of SYT-SSX2 effect on b-catenin signaling. Significantly, an E1A mutant (E1A D2-36) unable to bind p300 rescued SYT-SSX2 stimulatory effect by more than 50% (Figure 4b ).
We were next interested in investigating whether the transcription coactivating effect of SYT-SSX2 is context-specific, or a general feature of the fusion protein conferred on all gene promoters. To answer this SYT-SSX2 regulates b-catenin location and function D Pretto et al question, we compared the three SYT-derived proteins for their ability to stimulate p300 activity in a GALpromoter reporter assay. Neither SYT, SYT-SSX2, nor SYTdl8 exerted any significant change on GAL-p300 function (Figure 4c ). Altogether, these results suggest that the translocation protein, through its SSX region, acquires a positive gain of function that stimulates b-catenin signaling. Intact p300 function seems to be required for such effect. Failure of SYT-SSX2 to enhance transcription driven by the GAL promoter indicates that the SYT-SSX2 stimulatory effect is context-dependent, with b-catenin as one of its specific targets. Both proteins may form a transcriptionally active complex in the nucleus.
SYT-SSX2 regulates b-catenin function in primary human synovial sarcoma cells
We next endeavored to explore the biological significance of our findings as they applied to the cancer itself and whether the regulation of b-catenin localization and signaling by exogenous SYT-SSX2 seen in NIH3T3 is a reflection of actual events in synovial sarcoma. For this, we assayed primary human synovial sarcoma cells (Syn-1 with an SYT-SSX2 translocation). As reported previously, accumulation of b-catenin is frequently observed in synovial sarcomas (Hasegawa et al., 2001) . Therefore, we were not surprised to discover b-catenin in approximately 90% of untreated Syn-1 nuclei. Specific depletion of the SYT-SSX2 protein by transient RNA interference (RNAi) resulted in the disappearance of more than half the nuclear b-catenin from 98% of Syn-1 nuclei (Figure 5a , panel b-catenin and merge, and panel 5b). The 38% nuclear enrichment of cellular b-catenin in the control cells (INV) dropped to 17% in SiRNA cells (Si-SSX2). Meanwhile, the steady-state levels of total cellular b-catenin remained constant (Figure 5b and c, insets; b-catenin), suggesting that SYT-SSX2 likely influences b-catenin function primarily by controlling its cellular compartmentalization rather than its expression. We then used the TOP-FLASH reporter assay to test whether the nuclear exit of b-catenin from Syn-1 RNAi cells resulted in a concomitant decrease in its signaling. We observed that Syn-1 cells contained a constitutively active b-catenin/ TCF4 complex. Upon RNAi of SYT-SSX2, the endogenous b-catenin-specific TOP-FLASH activity was reduced to background FOP-FLASH levels (Figure 5c ).
To summarize, based on our SYT-SSX2 RNAi data in Syn-1 cells, we conclude that in synovial sarcoma bcatenin accumulates in the nucleus and is constitutively active. Reversal of these two processes upon depletion of Figure 4 p300-dependent stimulation of b-catenin signaling by SYT-SSX2. (a) Transcription activation studies in transfected NIH3T3 cells using the TOP-FLASH reporter (a luciferase reporter gene with an optimized TCF binding site) assay. FOP-FLASH (luciferase reporter gene with a mutated and inactive TCF site) was included for specificity. The indicated amounts of transfected plasmids were included in a total of 5 mg of transfected DNA of which 0.5 mg of CMV-b-GAL was used for internal control. The difference in amount of transfected DNA was compensated for with POZ backbone vector. Luciferase activities were measured 48 h post-transfection. All activities were measured relative to background levels obtained with POZ vector alone. Inset shows the protein levels of the transfected POZ-derived cDNAs by immunoblotting (IB) with FLAG M2 Ab. Similar activation results were obtained in at least five independent experiments. (b) Transfections and activation assays were conducted as described in (a), with the excepted addition of the indicated amounts of E1A and E1A D2-36. (c) Activation studies in NIH3T3 cells were conducted as described above and as indicated in the figure. In total, 0.5 mg of GAL-luciferase reporter vector and 5 mg of total transfected DNA were used. All activities were measured relative to GAL-p300.
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SYT-SSX2 in the primary cancer cells implies that the translocation protein is directly responsible for both, and this could represent part of its function in tumor initiation.
Discussion
In this report, we describe a new regulation of b-catenin function by a cancer translocation protein, SYT-SSX2.
Exogenous expression of SYT-SSX2 in mesenchymal cells induces accumulation of b-catenin in the nucleus where both proteins form an active complex. Depletion of SYT-SSX2 in primary synovial sarcoma cells reverses this process and inactivates b-catenin signaling. The effect of the fusion protein on b-catenin localization and function appeared to be independent of canonical Wnt and the signaling pathways known to exert similar events.
b-catenin transduces the Wnt pathway by translocating to the nucleus and associating with TCF factors. In SYT-SSX2 regulates b-catenin location and function D Pretto et al development it controls cell fate determination, axis formation and stem cell differentiation. In somatic cells, constitutive activation of b-atenin is oncogenic (Moon et al., 2002) . For these events b-catenin makes the critical switch between adhesion and nuclear signaling. The mechanism of b-catenin nuclear shuttling is still largely unknown and an active area of research is currently to identify the cellular factors involved in escorting b-catenin to the nucleus and those that help anchor it on the chromatin for its transcriptional activation. Two such factors have recently been isolated in Drosophila: Legless (the human oncogene BCL9-2 homolog) and Pypogus. The former is required for targeting b-catenin to the nucleus and the latter for anchoring it and providing chromatin access to b-catenin or TCF. There, all three proteins are thought to form a quaternary active complex with TCF (Bienz, 2004) . SYT-SSX2 is primarily an obligate nuclear chromatin binding protein. Thus, its ability to direct b-catenin to a subset of its nuclear foci implies that either it escorts bcatenin to the nucleus in a fashion similar to Legless/ BCL9-2 or it activates an inappropriate pathway that induces a yet unknown cellular protein to accompany bcatenin to the nucleus, where, like Pypogus, SYT-SSX2 anchors it on chromatin. Conversely, SYT-SSX2 could be retaining b-catenin in the nucleus by overriding the function of its tumor suppressor exporters such as APC or Axin. We are currently exploring these eventual scenarios.
When observed in various human tumors or as a result of oncogenic signaling pathways, nuclear accumulation of b-catenin is usually accompanied by an inappropriate activation of its signaling (D'Amico et al., 2000; Persad et al., 2001; Patturajan et al., 2002; Thompson et al., 2002; Tissier et al., 2005) . The outcome of such activation varies depending on the cellular context. Our data describing b-catenin nuclear exit consequent to SYT-SSX2 depletion in synovial sarcoma cells and the formation of a transcriptionally active in vivo complex that contains b-catenin and SYT-SSX2, imply that the sarcoma chimeric protein contributes to cancer formation by activating one of b-catenin target programs. Identifying the genes activated by the SYT-SSX2/b-catenin complex in a microarray analysis will be key in determining such programs. These studies are underway. The transcription coactivator p300 and components of the SWI/SNF chromatin remodeling complex such as BRG1, are likely candidates for acting as protein bridges in the active complex. Both SYT-SSX2 and b-catenin are able to associate with them directly. Moreover, both BRG1 (Barker et al., 2001 ) and p300 (Miyagishi et al., 2000) have been shown to regulate b-catenin signaling.
As illustrated in our colocalization studies, b-catenin is not the only partner of SYT-SSX2. It is present in a subset of SYT-SSX2-containing nuclear bodies. Therefore, in order to determine the b-catenin proper biological function affected by SYT-SSX2 in synovial sarcoma, an informative approach will be to generate extensive gene expression profiles of Syn-1 cells lacking SYT-SSX2 or b-catenin and identify the common targets and oncogenic signaling pathways activated by the two oncogenes, SYT-SSX2 and b-catenin.
Finally, synovial sarcoma is an aggressive tumor resistant to conventional therapy. As in other neoplasms characterized by a simple and distinct cytogenetic defect such as leukemias, translocation proteins provide an ideal target for therapy. Reversal of b-catenin functions by RNAi of SYT-SSX2 in Syn-1 cells suggests an active role of the fusion protein in b-catenin deregulation commonly detected in cases of synovial sarcoma. In this regard, b-catenin signaling is an intriguing candidate for therapeutic intervention in this cancer.
Materials and methods
Cells, lysis, immunoprecipitation and reagents NIH3T3 cells were grown in DMEM with 10% FCS. Syn-1 cells are primary human synovial sarcoma cells (a kind gift from Jonathan Fletcher; Brigham and Women's Hospital, Boston, USA). They were cultured in RPMI 1640 supplemented with 20% FCS. To assess protein expression levels, cells were lysed in RIPA buffer (50 mM Tris 7.5, 150 mM NaCl, 1% DOC, 1% Triton X-100, 0.1% SDS, 1 mM DTT) for 30 min at 41C. Lysates were then boiled in 2 Â sample buffer and equal protein amounts loaded on SDS-PAGE. For immunoprecipitation (IP), cells were lysed in 150 NTN buffer (20 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP40), then pelleted to remove insoluble material. The resulting supernatant was incubated with primary antibody (Ab) for 4 h at 41C, and, where needed, protein A-Sepharose beads (Amersham Biosciences, Uppsla, Sweden) were added to purify the immunocomplex. After three washes with 150 NTN, the beads were boiled in sample buffer.
SV11 is a SYT-specific monoclonal antibody raised against the COOH-terminal region (residues: 331-387; Jim de Caprio lab; Dana Farber Cancer Institute, Boston, MA, USA). B56 is an SSX-specific polyclonal antibody raised against the peptide HRLRERKQLVI (Open Biosystems, Huntsville, AL, USA). Rabbit b-catenin (C2206) and HA (H 6908), as well as the mouse a-tubulin (T 5168) and FLAG (M2 and M2-affinity gel) Abs were all purchased from Sigma (Saint Louis, MO, USA). Mouse anti-b-catenin (C19220) and HRPO-phosphotyrosine (P11625-050) Abs were obtained from BD Biosciences (San Diego, CA, USA). Rabbit anti-b-catenin (H-102) and mouse cyclin D1 (sc-450) were acquired from Santa Cruz, Santa Cruz, CA, USA). Anti-MYC tag (9E10) was kindly provided by David Livingston (Dana Farber cancer Institute, Boston, USA). Rabbit anti-MYC (06-340) and mouse anti-TCF4 (clone 6H5-3) were purchased from Upstate (Lake Placid, NY, USA). Mouse anti-dephospho-b-catenin Ab (8E4) was obtained from A.G. Scientific, San Diego, CA, USA. UO126, SB203580 and LY294002 were purchased from Calbiochem, La Jolla, CA, USA.
Cell fractionation
After 2 washes with PBS, 5 Â 10 6 Syn-1 cells were pelleted then suspended and swollen in 2 volumes of hypotonic buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl and 0.5 mM DTT) for 10 min. Nuclei and cytoplasmic fractions were obtained by brief lysing with 5% NP-40 (2 ml of 5% NP-40 for 50 ml of lysate), then separated by slow centrifugation (2500 rpm for 5 min). All procedures were performed on ice.
After an additional wash of the nuclei with hypotonic buffer, SYT-SSX2 regulates b-catenin location and function D Pretto et al both fractions were boiled in protein sample buffer and analysed on SDS-PAGE.
Cloning of SYT and SYT-SSX expression vectors GST-TCF4 was a kind gift from Lynn Matrisian (Vanderbilt University, Nashville, TN, USA). GST-SYT was previously described (Eid et al., 2000) . GST-SYT-SSX2 was generated as follows. The SSX component of the oncogene SYT-SSX2 was amplified by RT-PCR (Invitrogen, Carlsbad, CA, USA) from a human synovial sarcoma tumor. The primers used were JE-41: 5 0 -GCGCAGGCCTTATGGATATGACCAG-3 0 and JE-42: 5 0 -GCGCGAATTCTTACTCGTCATCTTCCTC-3 0 . GST-SYT-SSX2 was constructed by ligating the SSX2 PCR product cut with Stu1 and EcoR1, the Sma1/Stu1 SYT-coding fragment derived from pCDNA3/SYT-HA, and the PGEX-2T digested with Sma1 and EcoR1. Wt b-catenin-expressing vector (pCI-neo-b-cateninXL) was a kind gift from Bert Vogelstein (Johns Hopkins Hospital, Baltimore, MD, USA). The POZ-based expression vectors (a kind gift from Pat Nakatani; Dana Farber Cancer Institute, Boston, USA) were constructed by inserting, in frame, between the Not1 and the Xho1 sites of POZ, SYT, SYT-SSX and SYTdl8. SYT and SYTdl8 were PCR products amplified from GST-SYT, and SYT-SSX from GST-SYT-SSX. The primers used were, SYT-5 0 : 5 0 -GCGCCTCGAGTAGACCACCATGTCTGTGGCTT TCGCGGCC-3 0 and SYT-3 0 : 5 0 -GCGCGCGGCCGCCTGCT GGTAATTTCCATA-3 0 for FL-SYT; SYT-5 0 and D8-3 0 : 5 0 -GCGCGCGGCCGCCTGGTCATATCCATAAGG-3 0 for SYT-D8; and SYT-5 0 with SSX-3 0 : 5 0 -GCGCGCGGCCGCC TCGTCATCTTCCTCAGG-3 0 for SYT-SSX. All three proteins acquired at the COOH-terminus both an HA and a FLAG tags built in POZ. Cloned fragments were verified by sequence analysis.
In vitro binding assay 35 S-labeled in vitro-translated (IVT) b-catenin was generated from wt-b-catenin plasmid following vendor's instructions (Promega, Madison, WI, USA). For the in vitro assay, 5 ml of IVT b-catenin were incubated with GST, GST-SYT, GST-SYT-SSX and GST-TCF4 immobilized on glutathione beads. The binding buffer was 25 mM Tris 7.5, 150 mM NaCl, 1 mM DTT and 0.1% NP40. The binding reaction was carried at 41C for 30 min, after which the complexes were washed three times in binding buffer without DTT. The beads were then boiled in Laemmli buffer, resolved on SDS-PAGE and subjected to autoradiography. Of IVT b-catenin, 2 ml, were included in the input lane.
Retroviral infection
Transient retroviral infections were conducted using the phoenix packaging cell system, as described previously (Ireton et al., 2002) . The virus was harvested 2 days after transfection and experimental analyses were conducted on NIH3T3 cells 2 days after infection.
Immunofluorescence Cells were plated on cover slips coated with 0.2% gelatin in 1 Â PBS. They were fixed for 15 min in PBS containing 3% paraformaldehyde and 2% sucrose. After permeabilization with PBS/0.2% Triton X-100 for 5 min, they were blocked with 3% goat serum in PBS and incubated with primary Abs for 2 h at room temperature. After three washes with PBS, coverslips were incubated with Alexa-conjugated 21 Abs (Molecular Probes, Eugene, OR, USA) for 30 min, washed and mounted with DAPI-Vectastain (Vector, Burlingame, CA, USA). Zeiss (Axioplan 2) fluorescence microscope was used for cell visualization and counting.
RNAi of SYT-SSX2 in synovial sarcoma (Syn-1) cells RNAi in SYN-1 cells was performed as described previously (Elbashir et al., 2001) , using 3 ml of oligofectamine (Invitrogen) and 10 ml of the indicated RNA duplex for each well. The specific SSX2 sequence targeted for SiRNA was 5 0 -AAC CAACTACC TCTGAGAAGA-3 0 (Si-SSX2). The nonspecific control sequence (INV) was 5 0 -TCCTGGGTATCCGTATAA GAC-3 0 (Qiagen, Valencia, CA, USA). INV corresponds to an inverted sequence selected from the SYT cDNA.
Activation/luciferase assays For activation studies in Figure 4 , NIH3T3 cells were transfected using the Superfect (Qiagen) reagent according to manufacturer's instructions. Experiments were conducted in triplicates. Luciferase activities were measured using the Luciferase reporter assay (Promega, Madison, WI, USA).
